IFNAR1 and neoplasm: Authors have reported that genetic or pharmacological stabilization of IFNAR1 can improve CRC patients’ response to chimeric antigen receptor treatment and inhibition of programmed cell death protein 1 (PD-1), which, in turn increases the efficacy of tumor immunotherapy by augmenting the activity and the number of cytotoxic T cells in the tumor niche [120].